Accelerate Diagnostics Inc (AXDX) concluded trading on Thursday at a closing price of $0.14, with 8.15 million shares of worth about $1.14 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -92.62% during that period and on May 08, 2025 the price saw a loss of about -70.39%. Currently the company’s common shares owned by public are about 25.19M shares, out of which, 15.31M shares are available for trading.
Stock saw a price change of -72.94% in past 5 days and over the past one month there was a price change of -76.22%. Year-to-date (YTD), AXDX shares are showing a performance of -88.50% which decreased to -85.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.45 but also hit the highest price of $2.09 during that period. The average intraday trading volume for Accelerate Diagnostics Inc shares is 41.93K. The stock is currently trading -73.42% below its 20-day simple moving average (SMA20), while that difference is down -82.22% for SMA50 and it goes to -89.67% lower than SMA200.
Accelerate Diagnostics Inc (NASDAQ: AXDX) currently have 25.19M outstanding shares and institutions hold larger chunk of about 18.14% of that.
The stock has a current market capitalization of $3.48M and its 3Y-monthly beta is at 0.27. It has posted earnings per share of -$2.21 in the same period. It has Quick Ratio of 0.62. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AXDX, volatility over the week remained 36.02% while standing at 17.36% over the month.
Stock’s fiscal year EPS is expected to drop by -1.88%.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on March 09, 2022 offering a Hold rating for the stock and assigned a target price of $5 to it. On August 07, 2020, Craig Hallum Upgrade their recommendations, while on September 27, 2019, JP Morgan Downgrade their ratings for the stock with a price target of $16. Stock get a Neutral rating from JP Morgan on November 07, 2018.
